Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
3 "Younak Choi"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study
Younak Choi, Do-Youn Oh, Kyubo Kim, Eui Kyu Chie, Tae-Yong Kim, Kyung-Hun Lee, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Sung Whan Ha, Yung-Jue Bang
Cancer Res Treat. 2016;48(3):1045-1055.   Published online October 16, 2015
DOI: https://doi.org/10.4143/crt.2015.226
AbstractAbstract PDFPubReaderePub
Purpose
The optimal treatment strategy for locally advanced pancreatic cancer (LAPC), particularly the role of concurrent chemoradiotherapy (CCRT), remains debatable. We compared the clinical outcomes of CCRT and palliative chemotherapy alone (CA) in patients with unresectable LAPC. Materials and Methods Patients with LAPC who were consecutively treated between 2003 and 2010 were included. Resectability was evaluated according to National Comprehensive Cancer Network ver. 1.2012. The clinical outcomes for each treatment group (CCRT vs. CA) were evaluated retrospectively.
Results
Sixty-three patients (58.9%) and 44 patients (41.1%) were treated with CCRT and CA, respectively. The CCRT cohort included patients who were treated with CCRT with or without chemotherapy backbone (CCRT alone, induction chemotherapy-CCRT, CCRT-maintenance chemotherapy, and induction-CCRT-maintenance chemotherapy). Median progression-free survival (PFS) and overall survival (OS) of all patients were 7.2 months and 13.1 months. PFS of the CCRT and CA groups was 9.0 months and 4.4 months, respectively (p=0.020). OS of the CCRT and CA groups was 15.4 months and 9.3 months, respectively (p=0.011). In multivariate analysis, the adjusted hazard ratio of CCRT was 0.536 (p=0.003) for OS and 0.667 (p=0.078) for PFS. Although the pattern of failure was similar in the CCRT and CA groups, the times to both local and distant failure were significantly longer in the CCRT group. Conclusion In patients with unresectable LAPC, those who underwent CCRT during their entire treatment courses had longer OS than patients treated with chemotherapy alone.

Citations

Citations to this article as recorded by  
  • Dose-Escalated SBRT for Borderline and Locally Advanced Pancreatic Cancer: Resectability Rate and Pathological Results of a Multicenter Prospective Study
    Barbara Salas-Salas, Laura Ferrera-Alayon, Alberto Espinosa-Lopez, Maria Luisa Perez-Rodriguez, Antonio Alayón Afonso, Andres Vera-Rosas, Gabriel Garcia-Plaza, Rodolfo Chicas-Sett, Maria Soledad Martinez-Martin, Elisa Salcedo, Andrea Kannemann, Marta Llor
    Cancers.2025; 17(2): 191.     CrossRef
  • Dose-escalated SBRT for borderline and locally advanced pancreatic cancer. Feasibility, safety and preliminary clinical results of a multicenter study
    B. Salas, L. Ferrera-Alayón, A. Espinosa-López, A. Vera-Rosas, E. Salcedo, A. Kannemann, A. Alayon, R. Chicas-Sett, M. LLoret, P.C. Lara
    Clinical and Translational Radiation Oncology.2024; 45: 100753.     CrossRef
  • Survival benefits of radiotherapy in locally advanced unresectable and metastatic pancreatic cancer: a single-institution cohort and SEER database analysis
    Bi-Yang Cao, Le-Tian Zhang, Chen-Chen Wu, Jing Wang, Lin Yang
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Comparing concurrent chemoradiotherapy, 125I seed implantation combined with chemotherapy, and chemotherapy alone efficacy in treating unresectable locally advanced pancreatic cancer
    Yanfen Zheng, Rui Huang, Wenxue Zou, Chao Liu, Hongxin Niu, Jinbo Yue
    Precision Radiation Oncology.2022; 6(2): 144.     CrossRef
  • Concurrent Nab-paclitaxel and Radiotherapy
    William T. Arscott, Kevin T. Nead, Adham Bear, Sriram Venigalla, Jacob Shabason, John N. Lukens, John P. Plastaras, Andrzej Wojcieszynski, James Metz, Mark O’Hara, Kim A. Reiss, Ursina Teitelbaum, Arturo Loaiza-Bonilla, Jeffrey Drebin, Major K. Lee, Stuti
    American Journal of Clinical Oncology.2021; 44(9): 469.     CrossRef
  • Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer
    Mei Hua Jin, Ah-Rong Nam, Ji Eun Park, Ju-Hee Bang, Yung-Jue Bang, Do-Youn Oh
    Cancer Research and Treatment.2020; 52(1): 149.     CrossRef
  • Current trends and issues of conversion surgery for patients with locally advanced unresectable pancreatic cancer
    Toshimichi ASANO, Satoshi HIRANO, Toru NAKAMURA, Takehiro NOJI, Keisuke OKAMURA, Takahiro TSUCHIKAWA, Yuma EBIHARA, Toshiaki SHICHINOHE
    Suizo.2018; 33(1): 48.     CrossRef
  • Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment
    Toshimichi Asano, Satoshi Hirano, Toru Nakamura, Keisuke Okamura, Takahiro Tsuchikawa, Takehiro Noji, Yoshitsugu Nakanishi, Kimitaka Tanaka, Toshiaki Shichinohe
    Journal of Hepato-Biliary-Pancreatic Sciences.2018; 25(7): 342.     CrossRef
  • Which patients with locally advanced pancreatic cancer treated with induction chemotherapy are most likely to benefit from post-induction chemoradiotherapy?
    Sophie Otter, Irene Chong, Ria Kalaitzaki, Diana Tait
    International Journal of Hepatobiliary and Pancreatic Diseases.2018; 8(1): 1.     CrossRef
  • Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy
    Yi-Jun Kim, Hyeon Kang Koh, Eui Kyu Chie, Do-Youn Oh, Yung-Jue Bang, Eun Mi Nam, Kyubo Kim
    International Journal of Clinical Oncology.2017; 22(6): 1069.     CrossRef
  • Risk factors of liver metastasis from advanced pancreatic adenocarcinoma: a large multicenter cohort study
    Dong S., Wang L., Guo Y. B., Ying H. F., Shen X. H., Meng Z. Q., Chen Hao, Chen Q. W., Li Z. S.
    World Journal of Surgical Oncology.2017;[Epub]     CrossRef
  • Risk factors for latent distant organ metastasis detected by staging laparoscopy in patients with radiologically defined locally advanced pancreatic ductal adenocarcinoma
    Ilhan Karabicak, Sohei Satoi, Hiroaki Yanagimoto, Tomohisa Yamamoto, Satoshi Hirooka, So Yamaki, Hisashi Kosaka, Kentaro Inoue, Yoichi Matsui, Masanori Kon
    Journal of Hepato-Biliary-Pancreatic Sciences.2016; 23(12): 750.     CrossRef
  • 12,148 View
  • 137 Download
  • 11 Web of Science
  • 12 Crossref
Close layer
The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy
Younak Choi, Tae-Yong Kim, Do-Youn Oh, Kyung-Hun Lee, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Yung-Jue Bang
Cancer Res Treat. 2016;48(1):171-179.   Published online March 13, 2015
DOI: https://doi.org/10.4143/crt.2014.292
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
A causal relationship between diabetes mellitus (DM) and pancreatic cancer is well established. However, in patients with advanced pancreatic cancer (APC) who receive palliative chemotherapy, the impact of DM on the prognosis of APC is unclear. Materials and Methods We retrospectively enrolled APC patients who received palliative chemotherapy between 2003 and 2010. The patients were stratified according to the status of DM, in accordance with 2010 DM criteria (American Heart Association/American Diabetes Association). DM at least 2 years’ duration prior to diagnosis of APC was defined as remote-onset DM (vs. recent-onset).
Results
Of the 349 APC patients, 183 (52.4%) had DM. Among the patients with DM, 160 patients had DM at the time of diagnosis of APC (remote-onset, 87; recent-onset, 73) and the remaining 23 patients developed DM during treatment of APC. Ultimately, 73.2% of patients (134/183) with DM received antidiabetic medication, including metformin (56 patients, 41.8%), sulfonylurea (62, 45.5%), and insulin (43, 32.1%). In multivariate analysis, cancer extent (hazard ratio [HR], 1.792; 95% confidence interval [CI], 1.313 to 2.445; p < 0.001) showed association with decreased overall survival (OS), whereas a diagnosis of DM (HR, 0.788; 95% CI, 0.615 to 1.009; p=0.059) conferred positive tendency on the OS. Metformin treatment itself conferred better OS in comparison within DM patients (HR 0.693; 95% CI, 0.492 to 0.977; p=0.036) and even in all APC patients (adjusted HR, 0.697; 95% CI, 0.491 to 1.990; p=0.044). Conclusion For APC patients receiving palliative chemotherapy, metformin treatment is associated with longer OS. Patients with DM tend to survive longer than those without DM.

Citations

Citations to this article as recorded by  
  • Metformin use and pancreatic ductal adenocarcinoma outcomes: a narrative review
    Dooyeon Lee, Mun Sem Liew, Spiros Fourlanos, Julian Choi
    ANZ Journal of Surgery.2025;[Epub]     CrossRef
  • Hyperglycemia predicts adverse prognosis in advanced pancreatic cancer patients
    Xinzhe Zhu, Huaxiang Xu, Zhiwen Xiao, He Liu, Quanxing Ni, Xianjun Yu, Guopei Luo
    Endocrine.2023; 79(2): 296.     CrossRef
  • Influence of diabetes mellitus and effectiveness of metformin on hepatocellular carcinoma
    Masafumi Ono, Koji Fujita, Kiyoyuki Kobayashi, Tsutomu Masaki
    Hepatology Research.2023; 53(7): 579.     CrossRef
  • Diabetes duration and weight loss are associated with onset age and remote metastasis of pancreatic cancer in patients with diabetes mellitus
    Minglei Ma, Wei Li, Lingling Xu, Fan Ping, Huabing Zhang, Yuxiu Li
    Journal of Diabetes.2022; 14(4): 261.     CrossRef
  • Diabetes Mellitus and Pancreatic Ductal Adenocarcinoma—Prevalence, Clinicopathological Variables, and Clinical Outcomes
    Anna Badowska-Kozakiewicz, Marta Fudalej, Daria Kwaśniewska, Marek Durlik, Anna Nasierowska-Guttmejer, Agata Mormul, Emilia Włoszek, Aleksandra Czerw, Tomasz Banaś, Andrzej Deptała
    Cancers.2022; 14(12): 2840.     CrossRef
  • Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studies
    Jing Yang, Hang Yang, Ling Cao, Yuzhen Yin, Ying Shen, Wei Zhu
    Medicine.2022; 101(49): e31799.     CrossRef
  • Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704
    Danielle S. Bitterman, Kathryn A. Winter, Theodore S. Hong, Charles S. Fuchs, William F. Regine, Ross A. Abrams, Howard Safran, John P. Hoffman, Al B. Benson, Timothy Kasunic, Mary Mulcahy, James F. Strauss, Thomas DiPetrillo, Philip J. Stella, Yuhchyau C
    International Journal of Radiation Oncology*Biology*Physics.2021; 109(1): 201.     CrossRef
  • Effect of type 2 diabetes mellitus on survival in metastatic pancreatic cancer
    Ayşegül SAKİN, Suleyman SAHİN, Abdullah SAKİN, Muhammed ATCİ, Çağlayan GEREDELİ, Şener CİHAN
    Journal of Surgery and Medicine.2021; 5(1): 17.     CrossRef
  • Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity
    Yongde Luo, Xiaokun Li, Jianjia Ma, James L. Abbruzzese, Weiqin Lu
    Cancers.2021; 13(4): 778.     CrossRef
  • Repurposing metformin for the treatment of gastrointestinal cancer
    Ademar Dantas Cunha Júnior, Arinilda Campos Bragagnoli, Felipe Osório Costa, José Barreto Campello Carvalheira
    World Journal of Gastroenterology.2021; 27(17): 1883.     CrossRef
  • Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
    Ondřej Fiala, Pavel Ostašov, Aneta Rozsypalová, Milan Hora, Ondrej Sorejs, Jan Šustr, Barbora Bendová, Ivan Trávníček, Jan Filipovský, Jindřich Fínek, Tomáš Büchler
    Cancer Management and Research.2021; Volume 13: 4077.     CrossRef
  • Magic of a Common Sugar Pill in Cancer: Can Metformin Raise Survival in Pancreatic Cancer Patients?
    Mallika Gyawali, Nanditha Venkatesan, Opemipo D Ogeyingbo, Renu Bhandari, Rinky A Botleroo, Roaa Kareem, Rowan Ahmed, Abeer O Elshaikh
    Cureus.2021;[Epub]     CrossRef
  • Identification of Key Genes Involved in Diabetic Peripheral Neuropathy Progression and Associated with Pancreatic Cancer


    Liumeng Jian, Guangda Yang
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 463.     CrossRef
  • Oncological benefit of metformin in patients with pancreatic ductal adenocarcinoma and comorbid diabetes mellitus
    Fumihiro Terasaki, Teiichi Sugiura, Yukiyasu Okamura, Takaaki Ito, Yusuke Yamamoto, Ryo Ashida, Katsuhisa Ohgi, Katsuhiko Uesaka
    Langenbeck's Archives of Surgery.2020; 405(3): 313.     CrossRef
  • The Impact of obesity and diabetes mellitus on pancreatic cancer: Molecular mechanisms and clinical perspectives
    Bao Quoc Lam, Sushant K. Shrivastava, Anju Shrivastava, Sharmila Shankar, Rakesh K. Srivastava
    Journal of Cellular and Molecular Medicine.2020; 24(14): 7706.     CrossRef
  • Association between Metformin Use and Clinical Outcomes Following Pancreaticoduodenectomy in Patients with Type 2 Diabetes and Pancreatic Ductal Adenocarcinoma
    Daegwang Yoo, Nayoung Kim, Dae Wook Hwang, Ki Byung Song, Jae Hoon Lee, Woohyung Lee, Jaewoo Kwon, Yejong Park, Sarang Hong, Jong Woo Lee, Kyungyeon Hwang, Dakyum Shin, Eunyoung Tak, Song Cheol Kim
    Journal of Clinical Medicine.2020; 9(6): 1953.     CrossRef
  • The Role of Dysfunctional Adipose Tissue in Pancreatic Cancer: A Molecular Perspective
    Davide Brocco, Rosalba Florio, Laura De Lellis, Serena Veschi, Antonino Grassadonia, Nicola Tinari, Alessandro Cama
    Cancers.2020; 12(7): 1849.     CrossRef
  • Cohort Study of Antihyperglycemic Medication and Pancreatic Cancer Patients Survival
    Audrius Dulskas, Ausvydas Patasius, Donata Linkeviciute-Ulinskiene, Lina Zabuliene, Giedre Smailyte
    International Journal of Environmental Research and Public Health.2020; 17(17): 6016.     CrossRef
  • Relationships are between metformin use and survival in pancreatic cancer patients concurrent with diabetes
    Yu-Qi Shi, Xiao-Chong Zhou, Peng Du, Min-Yue Yin, Lan Xu, Wen-Jie Chen, Chun-Fang Xu
    Medicine.2020; 99(37): e21687.     CrossRef
  • Metformin Use and Pancreatic Cancer Survival among Non-Hispanic White and African American U.S. Veterans with Diabetes Mellitus
    Adetunji T. Toriola, Suhong Luo, Theodore S. Thomas, Bettina F. Drake, Su-Hsin Chang, Kristen M. Sanfilippo, Kenneth R. Carson
    Cancer Epidemiology, Biomarkers & Prevention.2020; 29(1): 169.     CrossRef
  • Metformin and pancreatic cancer survival: Real effect or immortal time bias?
    Min Wei, Yu Liu, Yongyi Bi, Zhi‐Jiang Zhang
    International Journal of Cancer.2019; 145(7): 1822.     CrossRef
  • The effect of diabetes mellitus on pharmacokinetics, pharmacodynamics and adverse drug reactions of anticancer drugs
    Habibeh Mashayekhi‐Sardoo, Amir Hooshang Mohammadpour, Homa Nomani, Amirhossein Sahebkar
    Journal of Cellular Physiology.2019; 234(11): 19339.     CrossRef
  • The impact of diabetes mellitus on clinical outcomes following chemotherapy for the patients with pancreatic cancer: a meta-analysis
    Jichun Ma, Jing Wang, Long Ge, Bo Long, Junqiang Zhang
    Acta Diabetologica.2019; 56(10): 1103.     CrossRef
  • Obesity and Pancreatic Cancer
    Mu Xu, Xiaoman Jung, O. Joe Hines, Guido Eibl, Yijun Chen
    Pancreas.2018; 47(2): 158.     CrossRef
  • Impact of Concurrent Medication Use on Pancreatic Cancer Survival—SEER-Medicare Analysis
    Muhammad S. Beg, Arjun Gupta, David Sher, Sadia Ali, Saad Khan, Ang Gao, Tyler Stewart, Chul Ahn, Jarett Berry, Eric M. Mortensen
    American Journal of Clinical Oncology.2018; 41(8): 766.     CrossRef
  • Metformin as an Adjunctive Therapy for Pancreatic Cancer: A Review of the Literature on Its Potential Therapeutic Use
    Philip J. Broadhurst, Andrew R. Hart
    Digestive Diseases and Sciences.2018; 63(11): 2840.     CrossRef
  • Exploring the bi-directional relationship between pancreatic cancer and diabetes mellitus: a retrospective study
    Kellam Harry, Yim Kein-Leong
    Journal of Diabetes & Metabolic Disorders.2018; 17(2): 247.     CrossRef
  • No association between metformin use and survival in patients with pancreatic cancer
    Martine A. Frouws, Babs G. Sibinga Mulder, Esther Bastiaannet, Marjolein M.J. Zanders, Myrthe P.P. van Herk-Sukel, Eleonora M. de Leede, Bert A. Bonsing, J. Sven. D. Mieog, Cornelis J.H. Van de Velde, Gerrit-Jan Liefers
    Medicine.2017; 96(10): e6229.     CrossRef
  • Chloride intracellular channel 1 regulates the antineoplastic effects of metformin in gallbladder cancer cells
    Yongchen Liu, Zheng Wang, Maolan Li, Yuanyuan Ye, Yi Xu, Yichi Zhang, Ruiyan Yuan, Yunpeng Jin, Yajuan Hao, Lin Jiang, Yunping Hu, Shili Chen, Fatao Liu, Yijian Zhang, Wenguang Wu, Yingbin Liu
    Cancer Science.2017; 108(6): 1240.     CrossRef
  • The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis
    Xiaogang Li, Tong Li, Zhiqiang Liu, Shanmiao Gou, Chunyou Wang
    Scientific Reports.2017;[Epub]     CrossRef
  • The Effect of Metformin on Mortality Among Diabetic Cancer Patients: A Systematic Review and Meta-analysis
    Xun Cao, Yaopan Wu, Jing Wang, Kuiyuan Liu, Xin Wang
    JNCI Cancer Spectrum.2017;[Epub]     CrossRef
  • Association of elevated risk of pancreatic cancer in diabetic patients: A systematic review and meta-analysis
    Jiaxin Tan, Yu You, Fei Guo, Jianhua Xu, Haisu Dai, Ping Bie
    Oncology Letters.2017; 13(3): 1247.     CrossRef
  • Pancreatic Carcinoma and Diabetes Mellitus
    Laszlo Czako
    Gastroenterology & Hepatology: Open Access.2017;[Epub]     CrossRef
  • Association between metformin use and mortality in patients with type 2 diabetes mellitus and localized resectable pancreatic cancer: a nationwide population-based study in korea
    Won Il Jang, Mi-Sook Kim, Shin Hee Kang, Ae Jung Jo, Yun Jung Kim, Ha Jin Tchoe, Chan Mi Park, Hyo Jeong Kim, Jin A Choi, Hyung Jin Choi, Eun-Kyung Paik, Young Seok Seo, Hyung Jun Yoo, Jin-Kyu Kang, Chul Ju Han, Yeon Ju Kim, Sang Beom Kim, Min Jung Ko
    Oncotarget.2017; 8(6): 9587.     CrossRef
  • Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis
    Ping-Ting Zhou, Bo Li, Fu-Rao Liu, Mei-Chao Zhang, Qian Wang, Yan-Yan Li, Ci Xu, Yuan-Hua Liu, Yuan Yao, Dong Li
    Oncotarget.2017; 8(15): 25242.     CrossRef
  • Effects of metformin on survival outcomes of pancreatic cancer: a meta-analysis
    Yi-Wei Dong, Yan-Qiang Shi, Li-Wen He, Xi-Yu Cui, Pei-Zhu Su
    Oncotarget.2017; 8(33): 55478.     CrossRef
  • Prognostic significance of anti-diabetic medications in pancreatic cancer: A meta-analysis
    Dong-Chu Zhou, Hui Gong, Chong-Qing Tan, Jian-Quan Luo
    Oncotarget.2017; 8(37): 62349.     CrossRef
  • Effects of metformin on survival outcomes of pancreatic cancer patients with diabetes: A meta-analysis
    Wenxiu Xin, Luo Fang, Qilu Fang, Xiaowei Zheng, Ping Huang
    Molecular and Clinical Oncology.2017;[Epub]     CrossRef
  • Obesity and Cancer: An Angiogenic and Inflammatory Link
    Dai Fukumura, Joao Incio, Ram C. Shankaraiah, Rakesh K. Jain
    Microcirculation.2016; 23(3): 191.     CrossRef
  • Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification
    Archana Bhaw-Luximon, Dhanjay Jhurry
    Journal of Cancer Research and Clinical Oncology.2016; 142(10): 2159.     CrossRef
  • Metformin Use Is Associated with Improved Survival in Patients Undergoing Resection for Pancreatic Cancer
    Marcelo Cerullo, Faiz Gani, Sophia Y. Chen, Joe Canner, Timothy M. Pawlik
    Journal of Gastrointestinal Surgery.2016; 20(9): 1572.     CrossRef
  • Effect of Diabetes on Survival after Resection of Pancreatic Adenocarcinoma. A Prospective, Observational Study
    Gianpaolo Balzano, Erica Dugnani, Alessandra Gandolfi, Marina Scavini, Valentina Pasquale, Francesca Aleotti, Daniela Liberati, Gaetano Di Terlizzi, Giovanna Petrella, Michele Reni, Claudio Doglioni, Emanuele Bosi, Massimo Falconi, Lorenzo Piemonti, Surin
    PLOS ONE.2016; 11(11): e0166008.     CrossRef
  • Type 2 diabetes mellitus is associated with increased risk of pancreatic cancer: A veteran administration registry study
    Issam Makhoul, Abdulraheem Yacoub, Eric Siegel
    SAGE Open Medicine.2016;[Epub]     CrossRef
  • Inhibitory effect of metformin combined with gemcitabine on pancreatic cancer cells in vitro and in vivo
    Yuqi Shi, Zhilong He, Zhenyu Jia, Chunfang Xu
    Molecular Medicine Reports.2016; 14(4): 2921.     CrossRef
  • Diabetes mellitus and metformin in hepatocellular carcinoma
    Koji Fujita, Hisakazu Iwama, Hisaaki Miyoshi, Joji Tani, Kyoko Oura, Tomoko Tadokoro, Teppei Sakamoto, Takako Nomura, Asahiro Morishita, Hirohito Yoneyama, Tsutomu Masaki
    World Journal of Gastroenterology.2016; 22(27): 6100.     CrossRef
  • High prevalence of diabetes mellitus and impaired glucose tolerance in liver cancer patients: A hospital based study of 4610 patients with benign tumors or specific cancers
    Chen Roujun, Yi Yanhua, Li Bixun
    F1000Research.2016; 5: 1397.     CrossRef
  • (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial
    Michele Reni, Erica Dugnani, Stefano Cereda, Carmen Belli, Gianpaolo Balzano, Roberto Nicoletti, Daniela Liberati, Valentina Pasquale, Marina Scavini, Paola Maggiora, Valeria Sordi, Vito Lampasona, Domenica Ceraulo, Gaetano Di Terlizzi, Claudio Doglioni,
    Clinical Cancer Research.2016; 22(5): 1076.     CrossRef
  • Can metformin improve ‘the tomorrow’ of patients treated for oesophageal cancer?
    L. Van De Voorde, L. Janssen, R. Larue, R. Houben, J. Buijsen, M. Sosef, B. Vanneste, M.-C. Schraepen, M. Berbée, P. Lambin
    European Journal of Surgical Oncology (EJSO).2015; 41(10): 1333.     CrossRef
  • Can metformin change the prognosis of pancreatic cancer? Retrospective study for pancreatic cancer patients with pre-existing diabetes mellitus type 2
    Sang Hoon Lee, Sang Hyun Yoon, Hee Seung Lee, Moon Jae Chung, Jeong Youp Park, Seung Woo Park, Si Young Song, Jae Bock Chung, Seungmin Bang
    Digestive and Liver Disease.2015;[Epub]     CrossRef
  • Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling
    Xinqun Chai, Hongpeng Chu, Xuan Yang, Yuanpu Meng, Pengfei Shi, Shanmiao Gou
    Scientific Reports.2015;[Epub]     CrossRef
  • Obesity and cancer, a case for insulin signaling
    Y Poloz, V Stambolic
    Cell Death & Disease.2015; 6(12): e2037.     CrossRef
  • 16,551 View
  • 136 Download
  • 47 Web of Science
  • 51 Crossref
Close layer
Cancer Treatment near the End-of-Life Becomes More Aggressive: Changes in Trend during 10 Years at a Single Institute
Younak Choi, Bhumsuk Keam, Tae Min Kim, Se-Hoon Lee, Dong-Wan Kim, Dae Seog Heo
Cancer Res Treat. 2015;47(4):555-563.   Published online February 16, 2015
DOI: https://doi.org/10.4143/crt.2014.200
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to investigate and compare cancer treatment near the end-of-life (EOL) over a 10-year period. Materials and Methods Patients with advanced solid cancer at Seoul National University Hospital who received palliative chemotherapy and had died were enrolled. We categorized the consecutive patients according to two time periods: 2002 (n=57) and 2012 (n=206). Aggressiveness of cancer treatment near the EOL was evaluated.
Results
The median patient age was 62, and 65.4% of patients (n=172) were male. Time from the last chemotherapy to death (TCD) was found to have been significantly shortened, from 66.0 days to 34.0 days during 10 years (p < 0.001); 17% of patients received molecular targeted agents as the last chemotherapy regimen in 2012. The proportion of patients who received intensive care unit care within the last month increased from 1.8% in 2002 to 19.9% in 2012 (p < 0.001), and emergency room visits within the last month also increased from 22.8% to 74.8% (p < 0.001). Although hospice referral increased from 9.1% to 37.4% (p < 0.001), timing of referral was delayed from median 53 days to 8 days before death (p=0.004). Use of targeted agents as the last chemotherapy for over-two-regimen users was associated with shortened TCD (hazard ratio, 2.564; p=0.002). Conclusion Cancer treatment near the EOL became more aggressive over 10 years.

Citations

Citations to this article as recorded by  
  • Factors Affecting Life-Sustaining Treatment Decisions and Changes in Clinical Practice after Enforcement of the Life-Sustaining Treatment (LST) Decision Act: A Tertiary Hospital Experience in Korea
    Yoon Jung Jang, Yun Jung Yang, Hoi Jung Koo, Hye Won Yoon, Seongbeom Uhm, Sun Young Kim, Jeong Eun Kim, Jin Won Huh, Tae Won Kim, Seyoung Seo
    Cancer Research and Treatment.2025; 57(1): 280.     CrossRef
  • Decreased aggressive care at the end of life among advanced cancer patients in the Republic of Korea: a nationwide study from 2012 to 2018
    Sara Kwon, Kyuwoong Kim, Bohyun Park, So-Jung Park, Hyun Jung Jho, Jin Young Choi
    BMC Palliative Care.2024;[Epub]     CrossRef
  • Patients’ Trajectory With Lung Cancer From Treatment Initiation to End-Of-Life: A Retrospective Cohort Study Using Claims Data in Japan
    Yuri Ogura, Masahiro Iwasaku, Mami Ishida, Yuki Katayama, Naoya Nishioka, Kenji Morimoto, Chie Yamamoto, Shinsaku Tokuda, Yoshiko Kaneko, Tadaaki Yamada, Hideya Yamazaki, Masayoshi Inoue, Hiroshi Ikai, Koichi Takayama
    Cancer Control.2024;[Epub]     CrossRef
  • The impact of palliative care consultation on reducing antibiotic overuse in hospitalized patients with terminal cancer at the end of life: a propensity score-weighting study
    Jeong-Han Kim, Shin Hye Yoo, Bhumsuk Keam, Dae Seog Heo
    Journal of Antimicrobial Chemotherapy.2023; 78(1): 302.     CrossRef
  • Trends in appropriateness of end-of-life care in people with cancer, COPD or with dementia measured with population-level quality indicators
    Robrecht De Schreye, Luc Deliens, Lieven Annemans, Birgit Gielen, Tinne Smets, Joachim Cohen, Lihua Li
    PLOS ONE.2023; 18(2): e0273997.     CrossRef
  • Quality of End-of-Life Care during the COVID-19 Pandemic at a Comprehensive Cancer Center
    Yvonne Heung, Donna Zhukovsky, David Hui, Zhanni Lu, Clark Andersen, Eduardo Bruera
    Cancers.2023; 15(8): 2201.     CrossRef
  • Cancer care patterns in South Korea: Types of hospital where patients receive care and outcomes using national health insurance claims data
    Dong‐Woo Choi, Sun Jung Kim, Seungju Kim, Dong Wook Kim, Wonjeong Jeong, Kyu‐Tae Han
    Cancer Medicine.2023; 12(13): 14707.     CrossRef
  • Frequency of anticancer drug use at the end of life: a scoping review
    Endre Szigethy, Rosario Dorantes, Miguel Sugrañes, Meisser Madera, Ivan Sola, Gerard Urrútia, Xavier Bonfill
    Clinical and Translational Oncology.2023; 26(1): 178.     CrossRef
  • Preferred versus Actual Place of Care and Factors Associated with Home Discharge among Korean Patients with Advanced Cancer: A Retrospective Cohort Study
    In Young Hwang, Yohan Han, Min Sun Kim, Kyae Hyung Kim, Belong Cho, Wonho Choi, Yejin Kim, Shin Hye Yoo, Sun Young Lee
    Healthcare.2023; 11(13): 1939.     CrossRef
  • Effectiveness of Palliative Care before Death in Reducing Emergency Care Utilization for Patients with Terminal Cancer and Trends in the Utilization of Palliative Care from 2005–2018
    Yi-Shiun Tsai, Wen-Chen Tsai, Li-Ting Chiu, Pei-Tseng Kung
    Healthcare.2023; 11(21): 2907.     CrossRef
  • Potentially inappropriate end-of-life care and its association with relatives’ well-being: a systematic review
    Laurien Ham, Ellis Slotman, Carolien Burghout, Natasja JH Raijmakers, Lonneke V van de Poll-Franse, Lia van Zuylen, Heidi P Fransen
    Supportive Care in Cancer.2023;[Epub]     CrossRef
  • Disparities in healthcare expenditures according to economic status in cancer patients undergoing end-of-life care
    Kyu-Tae Han, Woorim Kim, Seungju Kim
    BMC Cancer.2022;[Epub]     CrossRef
  • Reasons for chemotherapy discontinuation and end-of-life in patients with gastrointestinal cancer: A multicenter prospective AGEO study
    Lola-Jade Palmieri, Olivier Dubreuil, Jean-Baptiste Bachet, Isabelle Trouilloud, Christophe Locher, Romain Coriat, Frederick Moryoussef, Bruno Landi, Géraldine Perkins, Vincent Hautefeuille, Solène Doat
    Clinics and Research in Hepatology and Gastroenterology.2021; 45(1): 101431.     CrossRef
  • Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients
    Kyung-In Joung, Jong Hwa Song, Kangho Suh, Seung-Mi Lee, Ji Hyun Jun, Taehwan Park, Dong Churl Suh
    BioDrugs.2021; 35(1): 61.     CrossRef
  • Difficulties Doctors Experience during Life-Sustaining Treatment Discussion after Enactment of the Life-Sustaining Treatment Decisions Act: A Cross-Sectional Study
    Shin Hye Yoo, Wonho Choi, Yejin Kim, Min Sun Kim, Hye Yoon Park, Bhumsuk Keam, Dae Seog Heo
    Cancer Research and Treatment.2021; 53(2): 584.     CrossRef
  • Life-Sustaining Treatment States in Korean Cancer Patients after Enforcement of Act on Decisions on Life-Sustaining Treatment for Patients at the End of Life
    Young-Woong Won, Hwa Jung Kim, Jung Hye Kwon, Ha Yeon Lee, Sun Kyung Baek, Yu Jung Kim, Do Yeun Kim, Hyewon Ryu
    Cancer Research and Treatment.2021; 53(4): 908.     CrossRef
  • Healthcare Use during the Last Six Months of Life in Patients with Advanced Breast Cancer
    Renée. S. J. M. Schmitz, Sandra. M. E. Geurts, Khava. I. E. Ibragimova, Dominique. J. P. Tilli, Vivianne. C. G. Tjan-Heijnen, Maaike de Boer
    Cancers.2021; 13(21): 5271.     CrossRef
  • Impact of Palliative Care on Quality of End-of-Life Care Among Brazilian Patients With Advanced Cancers
    Talita Caroline de Oliveira Valentino, Carlos Eduardo Paiva, David Hui, Marco Antonio de Oliveira, Bianca Sakamoto Ribeiro Paiva
    Journal of Pain and Symptom Management.2020; 59(1): 39.     CrossRef
  • Aggressive End-of-Life Care and Symptom Relief Treatments in Terminally Ill Patients Who Had Discussed Withdrawal of Mechanical Ventilation: A Hospital-Based Observational Study
    Hsiao-Ting Chang, Ming-Hwai Lin, Chun-Ku Chen, Tzeng-Ji Chen, Shinn-Jang Hwang
    American Journal of Hospice and Palliative Medicine®.2020; 37(11): 897.     CrossRef
  • Chemotherapy and Tyrosine Kinase Inhibitors in the last month of life in patients with metastatic lung cancer: A patient file study in the Netherlands
    Adinda Mieras, Annemarie Becker‐Commissaris, H. Roeline W. Pasman, Anne‐Marie M. C. Dingemans, Edith V. Kok, Robin Cornelissen, Wouter Jacobs, Jan Willem Berg, Alle Welling, Brigitte A. H. A. Bogaarts, Lemke Pronk, Bregje D. Onwuteaka‐Philipsen
    European Journal of Cancer Care.2020;[Epub]     CrossRef
  • Modifiable Factors Associated with the Completion of Advance Treatment Directives in Hematologic Malignancy: A Patient–Caregiver Dyadic Analysis
    JinShil Kim, Jinny Park, Mee Ok Lee, Eun Young Park, Seongkum Heo, Jae Lan Shim
    Journal of Palliative Medicine.2020; 23(5): 611.     CrossRef
  • Changes of End of Life Practices for Cancer Patients and Their Association with Hospice Palliative Care Referral over 2009-2014: A Single Institution Study
    Hyun Jung Jho, Eun Jung Nam, Il Won Shin, Sun Young Kim
    Cancer Research and Treatment.2020; 52(2): 419.     CrossRef
  • Adverse events in deceased hospitalised cancer patients as a measure of quality and safety in end-of-life cancer care
    Ellinor Christin Haukland, Christian von Plessen, Carsten Nieder, Barthold Vonen
    BMC Palliative Care.2020;[Epub]     CrossRef
  • Implication of the Life-Sustaining Treatment Decisions Act on End-of-Life Care for Korean Terminal Patients
    Jung Sun Kim, Shin Hye Yoo, Wonho Choi, Yejin Kim, Jinui Hong, Min Sun Kim, Hye Yoon Park, Bhumsuk Keam, Dae Seog Heo
    Cancer Research and Treatment.2020; 52(3): 917.     CrossRef
  • Status and cost analysis of antimicrobial treatment of terminally ill patients with hematological malignancy in an acute hospital
    Miyuki Chiba, Miyako Negishi, Sanae Miyagawa, Satoru Suzuki, Emiko Sasai, Kazunori Sugai, Shotaro Hagiwara
    Journal of Infection and Chemotherapy.2020; 26(12): 1288.     CrossRef
  • Factors associated with the aggressiveness of care at the end of life for patients with cancer dying in hospital: a nationwide retrospective cohort study in mainland Portugal
    Diogo Martins-Branco, Silvia Lopes, Rita Canario, Joao Freire, Madalena Feio, Jose Ferraz-Goncalves, Gabriela Sousa, Nuno Lunet, Barbara Gomes
    ESMO Open.2020; 5(6): e000953.     CrossRef
  • Duration of palliative care before death in international routine practice: a systematic review and meta-analysis
    Roberta I. Jordan, Matthew J. Allsop, Yousuf ElMokhallalati, Catriona E. Jackson, Helen L. Edwards, Emma J. Chapman, Luc Deliens, Michael I. Bennett
    BMC Medicine.2020;[Epub]     CrossRef
  • Attitudes of the General Public, Cancer Patients, Family Caregivers, and Physicians Toward Advance Care Planning: A Nationwide Survey Before the Enforcement of the Life-Sustaining Treatment Decision-Making Act
    Hye Yoon Park, Young Ae Kim, Jin-Ah Sim, Jihye Lee, Hyewon Ryu, Jung Lim Lee, Chi Hoon Maeng, Jung Hye Kwon, Yu Jung Kim, Eun Mi Nam, Hyun-Jeong Shim, Eun-Kee Song, Kyung Hae Jung, Eun Joo Kang, Jung Hun Kang, Young Ho Yun
    Journal of Pain and Symptom Management.2019; 57(4): 774.     CrossRef
  • Economic burden of lung cancer: A retrospective cohort study in South Korea, 2002-2015
    Soo Min Jeon, Jin-Won Kwon, Sun Ha Choi, Hae-Young Park, Seil Sohn
    PLOS ONE.2019; 14(2): e0212878.     CrossRef
  • The Korean–Advance Directive Model and Factors Associated With Its Completion Among Patients With Hematologic Disorders
    Mee Ok Lee, Jinny Park, Eun Young Park, Youngji Kim, Eunjoo Bang, Seongkum Heo, JinShil Kim
    Journal of Hospice & Palliative Nursing.2019; 21(4): E10.     CrossRef
  • Are physicians on the same page about do-not-resuscitate? To examine individual physicians’ influence on do-not-resuscitate decision-making: a retrospective and observational study
    Yen-Yuan Chen, Melany Su, Shu-Chien Huang, Tzong-Shinn Chu, Ming-Tsan Lin, Yu-Chun Chiu, Kuan-Han Lin
    BMC Medical Ethics.2019;[Epub]     CrossRef
  • Lung cancer and end-of-life care: a systematic review and thematic synthesis of aggressive inpatient care
    Olivier Bylicki, Morgane Didier, Frederic Riviere, Jacques Margery, Frederic Grassin, Christos Chouaid
    BMJ Supportive & Palliative Care.2019; 9(4): 413.     CrossRef
  • Correlates of life-support treatment preferences among low-income home-based cancer management recipients
    JinShil Kim, Seongkum Heo, Mi Yeong Kim, Eun Young Park, Eun Ju Seo, Mee Ok Lee, Bo Yoon Jeong, Jung-Ah Lee
    European Journal of Oncology Nursing.2019; 43: 101665.     CrossRef
  • Determinants of Last-line Treatment in Metastatic Breast Cancer
    Marika Cinausero, Lorenzo Gerratana, Elisa De Carlo, Donatella Iacono, Marta Bonotto, Valentina Fanotto, Vanessa Buoro, Debora Basile, Maria Grazia Vitale, Karim Rihawi, Gianpiero Fasola, Fabio Puglisi
    Clinical Breast Cancer.2018; 18(3): 205.     CrossRef
  • Impact of Targeted Therapy on the Quality of End-of-Life Care for Patients With Non–Small-Cell Lung Cancer: A Population-Based Study in Taiwan
    Hsin-Yun Tsai, Kuo-Piao Chung, Raymond Nien-Chen Kuo
    Journal of Pain and Symptom Management.2018; 55(3): 798.     CrossRef
  • Outpatient Palliative Care and Aggressiveness of End-of-Life Care in Patients with Metastatic Colorectal Cancer
    Si Won Lee, Hyun Jung Jho, Ji Yeon Baek, Eun Kyung Shim, Hyun Mi Kim, Ji Yeon Ku, Eun Jung Nam, Yoon-Jung Chang, Hye Jin Choi, Sun Young Kim
    American Journal of Hospice and Palliative Medicine®.2018; 35(1): 166.     CrossRef
  • Differences in do-not-resuscitate orders, hospice care utilization, and late referral to hospice care between cancer and non-cancer decedents in a tertiary Hospital in Taiwan between 2010 and 2015: a hospital-based observational study
    Tzu-Chien Shih, Hsiao-Ting Chang, Ming-Hwai Lin, Chun-Ku Chen, Tzeng-Ji Chen, Shinn-Jang Hwang
    BMC Palliative Care.2018;[Epub]     CrossRef
  • Factors Associated with Early Referral to Palliative Care in Outpatients with Advanced Cancer
    Deepa Wadhwa, Gordana Popovic, Ashley Pope, Nadia Swami, Lisa W. Le, Camilla Zimmermann
    Journal of Palliative Medicine.2018; 21(9): 1322.     CrossRef
  • Qualitative study of patients’ decision-making when accepting second-line treatment after failure of first-line chemotherapy
    Jean-Louis Pujol, Benoît Roch, Caroline Roth, Jean-Pierre Mérel, Yvonne Drewes
    PLOS ONE.2018; 13(5): e0197605.     CrossRef
  • The Disease Burden of Lung Cancer Attributable to Residential Radon Exposure in Korean Homes
    Jong-Hun Kim, Mina Ha
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer
    Shin Hye Yoo, Bhumsuk Keam, Miso Kim, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo
    Cancer Research and Treatment.2018; 50(3): 720.     CrossRef
  • End-of-life care decisions using a Korean advance directive among cancer patient–caregiver dyads
    Shinmi Kim, Sujin Koh, Kwonoh Park, Jinshil Kim
    Palliative and Supportive Care.2017; 15(1): 77.     CrossRef
  • Long-term survival of out-of-hospital cardiac arrest patients with malignancy
    Saee Byel Kang, Kyung Su Kim, Gil Joon Suh, Woon Yong Kwon, Kyoung Min You, Min Ji Park, Jung-In Ko, Taegyun Kim
    The American Journal of Emergency Medicine.2017; 35(10): 1457.     CrossRef
  • Palliative care consultants’ ethical concerns with advanced cancer patients participating in phase 1 clinical trials. A case study
    Nunziata Comoretto, Ana Larumbe, Maria Arantzamendi, Carlos Centeno
    Progress in Palliative Care.2017; 25(5): 230.     CrossRef
  • Cases and Literature Review of Timing for Withdrawal of Palliative Chemotherapy
    Yun Jin Jeong, Do Yeun Kim
    The Korean Journal of Hospice and Palliative Care.2016; 19(1): 70.     CrossRef
  • Intensive care unit prognostic factors in critically ill patients with advanced solid tumors: a 3-year retrospective study
    Rui Xia, Donghao Wang
    BMC Cancer.2016;[Epub]     CrossRef
  • Herausforderungen der palliativen onkologischen Chirurgie
    Konrad K. Richter, U. Wedding
    Der Onkologe.2015; 21(11): 1074.     CrossRef
  • 12,720 View
  • 129 Download
  • 47 Web of Science
  • 47 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP